// App-Quantinova.ai

e21513 : Characterization of liver function tests (LFTs) following tebentafusp (tebe) in previously treated (2L+) metastatic uveal melanoma (mUM) patients (pts).

Researchers

Presenter

  • Takami Sato

Principal Investigators

  • Joseph J. Sacco

  • Alexander Noor Shoushtari

  • Jessica Cecile Hassel

  • Alexandra Ikeguchi

  • Leonel Fernando Hernandez-Aya

  • Paul Nathan

  • Matthew Rioth

  • Omid Hamid

  • Josep M. Piulats

  • Jason J. Luke

  • Douglas Buckner Johnson

  • Serge Leyvraz

  • Enrique Espinosa

  • Shaad Essa Abdullah

  • Daniel Sum

  • Sarah Lockwood

  • Patricia Mendez

  • Marcus O. Butler

Medical Centers

  • Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, Clatterbridge Cancer Centre, Merseyside, United Kingdom

  • Memorial Sloan Kettering Cancer Center, New York, NY, Department of Dermatology and National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany

  • University of Oklahoma Medical Center, Oklahoma City, OK, University of Michigain Health System, Ann Arbor, MI, Mount Vernon Cancer Centre, London, United Kingdom

  • University of Colorado Cancer Center, Aurora, CO, The Angeles Clinic and Research Institute, Los Angeles, CA

  • Instituto Catalan de Oncologia, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain

  • UPMC Hillman Cancer Center, Pittsburgh, PA, Vanderbilt University Medical Center, Nashville, TN, Charite-Universitätsmedizin Berlin, Berlin, Germany

  • Department of Medical Oncology, Doce de Octubre University Hospital, Madrid, Spain

  • Immunocore, Ltd, Abingdon, United Kingdom

  • Pivotal Statistics Ltd, Macclesfield, United Kingdom

  • Tumor Immunotherapy Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada

Locations

  • United Kingdom

  • Germany

  • Spain

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Uveal melanoma

Biomarkers

  • Aspartate aminotransferase

  • Alanine transaminase

  • Major Histocompatibility Complex, Class I, A

Drug/Treatment

  • IMCgp100

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • N/A

Study Id's

  • NCT02570308

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved